Management of eczematous dermatitis with amcinonide or betamethasone valerate. A double-blind comparative study.
A new topical corticosteroid formulation, 0.1 percent amcinonide cream, was compared with 0.1 percent betamethasone valerate cream in a double-blind, parallel study of the management of eczematous dermatitis. Both treatment groups showed statistically significant improvement in most symptoms and in overall disease status after one and two weeks of treatment. The amcinonide group had greater improvement in individual symptoms and significantly greater overall improvement than did the betamethasone valerate group. Side effects were few and minor in both groups. The amcinonide cream was found to be both safe and effective for the management of eczematous dermatitis.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000031:analogs & derivatives*; D001624:Betamethasone Valerate / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014221:Triamcinolone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D003517:Cyclopentanes; D014221:Triamcinolone; C012716:amcinonide; D001623:Betamethasone; D001624:Betamethasone Valerate